Patent DE-10317955-A1 (DE)
Title: Predicting responsiveness of a subject with breast cell proliferative disorder, useful for treating or differentiating breast cell proliferative disorders comprises analyzing methylation pattern of a genomic DNA from the subject
Inventor: FOEKENS JOHN
IPC: C12Q1/68
Filed: 2003-04-17
Abstract: Predicting the responsiveness of a subject with a cell proliferative disorder of the breast tissues to a therapy comprising analyzing the methylation pattern of a target nucleic acid by contacting at least one of the target nucleic acids in a biological sample obtained from the subject prior to or during treatment, is new. Predicting the responsiveness of a subject with a cell proliferative disorder of the breast tissues to a therapy comprising analyzing the methylation pattern of a target nucleic acid by contacting at least one of the target nucleic acids in a biological sample obtained from the subject prior to or during treatment, is new. The therapy for the cell proliferative disorder of the breast tissues comprises one or more drugs, which target the estrogen receptor pathway or are involved in estrogen metabolism, production, or secretion. The target nucleic acid comprises one or a combination of genes selected from STMN1, SFN, S100A2, TGFBR2, TP53, PTGS2, FGFR1, SYK, PITX2, GRIN2D, PSA, CGA, CYP2D6, MSMB, COX7A2L, VTN, PRKCD, ONECUT2, WBP11, CYP2D6, DAG1, ERBB2, S100A2, TFF1, TP53, TMEFF2, ESR1, SYK, RASSF1, PITX2, PSAT1, CGA or PCAF and/or their regulatory regions. Independent claims are also included for the following: (1) a nucleic acid consisting essentially of a sequence at least 18 bases in length selected from 132, 28, 16, 40 or 64 sequences (all sequences not given in the specification) or its complementary sequences; (2) an oligomer, preferably an oligonucleotide or peptide nucleic acid (PNA)-oligomer consisting essentially of at least one base sequence having at least 10 nucleotides which hybridizes to or is identical to one of the nucleic acid sequences above; (3) a set of oligomers comprising at least two oligomers; (4) manufacturing an arrangement of different oligomers (array) fixed to a carrier material for predicting the responsiveness of a subject with a cell proliferative disorder of the breast tissues to a therapy; (5) an arrangement of different oligomers (array) obtained from the method above; (6) an array of different oligonucleotide- and/or PNA-oligomer sequences, where the oligonucleotides are arranged on a plane solid phase in the form of a rectangular or hexagonal lattice; (7) a DNA- and/or PNA-array for predicting breast cell proliferative disorders' response to therapy comprising one or more drugs which target the estrogen receptor pathway or are involved in estrogen metabolism, production, or secretion by analysis of the methylation state of any of the CpG dinucleotides selected from 23 sequences (not given in the specification) and comprising at least one nucleic acid given above; and (8) a kit comprising a bisulfite (=disulfite, hydrogen sulfite) reagent as well as oligonucleotides and/or PNA-oligomers. ACTIVITY : Cytostatic. No biological data given. MECHANISM OF ACTION : Gene Therapy.